903PEFFECTIVENESS AND TOXICITY OF VINBLASTINE, CISPLATIN, CYCLOPHOSPHAMIDE, BLEOMYCIN, DOXORUBICIN AND ETOPOSIDE (VPCBAE) IN THE MANAGEMENT OF PATIENTS WITH SMALL CELL CARCINOMA OF THE OVARY-HYPERCALCEMIC TYPE (SCCOHT).

ABSTRACT Aim: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive malignant tumor with a poor prognosis. There is no consensus on the optimal treatment but it is hypothesized that multi-agent chemotherapy may extend survival. Methods: We performed a retrospective study of all patients evaluated at MD Anderson Cancer Center (MDACC) between May 2004 and April 2014 with the diagnosis of SCCOHT and identified 8 patients treated with vinblastine (6 mg/m2 on Day 1), cisplatin (90 mg/m2 on Day 1), cyclophosphamide (1000 mg/m2 on Day 2), bleomycin (15 units/m2 on Day 2), doxorubicin (45 mg/m2 IV on Day 3) and etoposide (200 mg/m2 on Day 3) (VPCBAE) followed by pegfilgrastim (6 mg) as primary treatment following surgery. Results: The median age at diagnosis was 28 years (range, 21-41). Five patients had stage I disease (63%), 2 had stage III disease (25%) and 1 had stage IV disease (12%). Seven patients (88%) underwent unilateral salpingo-oophorectomy due to a desire for fertility preservation. Five patients (63%) had an optimal tumor reduction with no visible residual disease, all stage I disease. All patients completed 6 chemotherapy cycles, and 7 (88%) had no evidence of disease after chemotherapy. Two patients (25%) died of disease and 2 patients (25%) are alive with disease. 4 patients (50%), all stage I disease, are alive without evidence of disease with a median follow up of 37.5 months (range, 5-60 months). Grade 3 to 4 toxicities included anemia (83%), neutropenia (67%), febrile neutropenia (33%), thrombocytopenia (67%) and nausea (17%). There were 6 hospitalizations, 5 treatment delays, 1 dose reduction, and a drug discontinuation (bleomycin due to grade 2 pulmonary fibrosis). Red cell and/or platelet transfusions were administered in 5 patients (83%). There were no treatment related deaths. Conclusions: VPCBAE combination is effective in patients with SCCOHT and associated toxicities are tolerable. Disclosure: All authors have declared no conflicts of interest.